Clinical trials: Prostate Cancer Patients Treated by Radiotherapy
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Localized Malignant Neoplasm
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery
Quality of life data following SBRT for prostate cancer has been obtained in only a small numbers of patients. A prospective study using validated quality of life questionnaires is needed to determine outcomes after treatment…
- Trial name
- PR-PROS (NCT01766492)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Georgetown University
Prostate Cancer
Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00949338
- Testing
- pre-procedural preparation
- Where
- Ireland
- Volunteers
- 183 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00547339
- Testing
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- University of Texas Southwestern Medical Center
Patients With Metastatic Castration-resistant Prostate Cancer
Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.
Patients undergo three diagnostic PET scans: 18F-FDG PET scan / 18F-Choline PET scan and 68Ga-PSMA PET scan. Following the diagnostic PET scans, and if patients' eligibility for 177Lu-PSMA-617 IVR treatment is confirmed, SPECT…
- Trial name
- GaLuPro (NCT06136377)
- Testing
- 177Lu-PSMA-617 PET scan
- Volunteers
- 35 people
- Sponsor
- Centre Georges Francois Leclerc
Prostate Cancer, Erectile Dysfunction
Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?
Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challenge.
- Trial name
- NCT00215631
- Testing
- tadalafil
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
New Treatment Modalities for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of four of the nowadays most established primary treatments for patients with clinically localized prostate cancer (active surveillance, robot-assisted radical…
- Trial name
- TTOPROST/OBS (NCT05523856)
- Testing
- Active Surveillance, Robot-Assisted Radical Prostatectomy, Intensity-Modulated Radiotherapy
- Volunteers
- 480 people
- Sponsor
- Fundacion IMIM
Urinary Problems, Prostate Cancer
Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Approximately 50%-95% of prostate cancer patients undergoing radiation therapy (RT) develop symptomatic urinary problems .These symptoms can significantly diminish a patient's quality of life during and shortly after therapy.
- Trial name
- NCT02220829
- Testing
- Preventive administration of Rapaflo, Standard Care
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00023829
- Testing
- bicalutamide, flutamide, releasing hormone agonist therapy
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002602
- Testing
- 3D-CRT
- Where
- 228 sites in United States, Canada
- Volunteers
- 1,084 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Tumor TARGET Prostate Cancer
Prostate cancer is common in males and may develop over the course of an individual's life. This cancer is often discovered at the time of routine physical examinations and/or blood work or on rectal examination.
- Trial name
- NCT01802242
- Testing
- Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy, No Active Treatment - completed Prior Radiation
- Where
- Canada
- Volunteers
- 85 people
- Sponsor
- University Health Network, Toronto
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
- Trial name
- HEATWAVE (NCT06067269)
- Testing
- Apalutamide, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00073970
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Surgery in Treating Patients With Prostate Cancer
RATIONALE: Prostatectomy may be an effective treatment for prostate cancer that has not responded to radiation therapy. PURPOSE: This phase II trial is studying how well prostatectomy works in treating patients with recurrent or…
- Trial name
- NCT00002938
- Testing
- conventional surgery
- Where
- 61 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00392535
- Testing
- conventional radiotherapy 74 Gy delivered in 37 fractions, hypofractionated radiation therapy 60 Gy in 20 fractions, hypofractionated radiation therapy 57 Gy in 19 fractions
- Where
- 26 sites in United Kingdom
- Volunteers
- 3,216 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two…
- Trial name
- NCT07325721
- Testing
- Hypofractionated radiation with a microboost
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for prostate cancer.
- Trial name
- NCT00010244
- Testing
- radiation therapy
- Where
- 19 sites in France
- Volunteers
- 306 people
- Sponsor
- UNICANCER